In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Investors consider value of Cubist's Trius, Optimer buys

This article was originally published in Scrip

Executive Summary

The market has had a full 24 hours to digest the news that Cubist Pharmaceuticals will buy two antibiotic developers to expand its portfolio of hospital-administered medicines, and investors weighed in with pretty clear opinions about the transactions, which will return up to $1.62 billion to Trius Therapeutics and Optimer Pharmaceuticals shareholders.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts